Completion of the clinical phase of randomized, double blind, placebo controlled pilot study conducted in India to evaluate safety and efficacy of orally administered IMA001 in sickle cell disease patients.
Imalia Demonstrates Protective Effect of IMA001 in Acute Vaso-occlusion Episode in Sickle Cell Disease Mice
Precinical proof-of-concept demonstration of the protective effect of the Administration for 36 days of